miércoles, 31 de octubre de 2012

Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009 - - Emerging Infectious Disease journal - CDC

Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009 - - Emerging Infectious Disease journal - CDC

Bookmark and Share
EID cover artwork EID banner
Table of Contents
Volume 18, Number 11–November 2012


Extensively Drug-Resistant Tuberculosis, Central China, 2007–2009

Suggested citation for this article
To the Editor: Multidrug-resistant (MDR) tuberculosis (TB), defined as TB caused by Mycobacterium tuberculosis resistant to isoniazid and rifampin, is threatening global control of TB. The emergence of extensively drug-resistant (XDR) TB, defined as MDR TB resistant to at least 1 quinolone and 1 of 3 injectable second-line drugs (kanamycin, amikacin, or capreomyin), further jeopardizes TB control and prevention.
In the People’s Republic of China, a country in which the economic cost of TB is high, incidence of MDR TB is higher (10%) (1) than the average global incidence (4.8%) (2). Published reports of XDR TB prevalence indicate that XDR TB is probably an underestimated problem in mainland China (37). China is a geographically large country, and the characteristics of drug resistance of TB might vary among provinces (2). Five regional surveys reported drug-resistance patterns of XDR TB in mainland China, and 3 were conducted in eastern China (37). To determine prevalence of XDT TB in central China, we characterized the resistance of MDR M. tuberculosis to second-line drugs, specifically identifying XDR strains, in Henan, a major province of central China. Henan Province has the country’s third largest provincial population (94 million) and high rates of drug resistance to any agent (35.5%) (2).
The bacterial population retrospectively analyzed in this study has been described (8). In brief, from 2007 through 2009, clinical isolates were collected consecutively by the Henan Center for Disease Control and Prevention TB surveillance system and screened for resistance to 4 first-line drugs. Proportion method–based drug susceptibility testing was conducted for the following critical concentrations: isoniazid 0.2 μg/mL, rifampin 40.0 μg/mL, ethambutol 2.0 μg/mL, and streptomycin 4.0 μg/mL. As a result of that study, 150 MDR TB isolates from TB patients were obtained. The genotyping of all MDR isolates was identified by variable number tandem repeat of mycobacterial interspersed repetitive units based on 16 loci with high discriminatory power.
For the study reported here, we performed additional drug susceptibility testing of 4 second-line drugs at the Henan Center for Disease Control and Prevention TB reference laboratory. We used the Löwenstein-Jensen proportion method, recommended by the World Health Organization, according to the following critical drug concentrations: ofloxacin 3.0 μg/mL, kanamycin 30.0 μg/mL, amikacin 30.0 μg/mL, and capreomycin 40.0 μg/mL (9).
Susceptibility results for all second-line drugs tested were reported for 143 (95.3%) of 150 MDR M. tuberculosis isolates. Among these 143 isolates, 49 (34.3%) were resistant to ofloxacin, 23 (16.1%) to kanamycin, 17 (11.9%) to amikacin, and 25 (17.5%) to capreomycin (Table). All 17 amikacin-resistant isolates were also resistant to kanamycin, and 16 were also resistant to capreomycin. Also among the 143 MDR isolates, 18 (12.6%) showed resistance to ofloxacin and at least 1 second-line injectable drug and were defined as XDR strains. All 18 XDR M. tuberculosis isolates were resistant to isoniazid, rifampin, streptomycin, and ofloxacin; 14 (77.8%), 16 (89.9%), 12 (66.7%), and 17 (94.4%) were resistant to ethambutol, kanamycin, amikacin, and caperomycin respectively. Twelve amikacin-resistant XDR isolates were also resistant to kanamycin and capreomycin (Table).
Genotyping results demonstrated that XDR strains were distributed diversely in the phylogenetic tree, suggesting that these strains evolved independently. Our results indicated that 12.6% of MDR TB isolates from Henan Province meet the definition of XDR TB, which is less than that found by hospital-based studies performed in Shandong (18.7%), Shanghai (30.0%), and Beijing (14.9%) (3,5,6) but higher than that found by 2 other studies conducted in Beijing and Shanghai (6.3% each) (4,7). The discrepancy between the percentages of XDR TB and MDR TB strains found in these studies might be explained by the probable inclusion of patients who had been previously treated and patients with chronic TB.
Previous studies found high cross-resistance among all 3 second-line injectable drugs in MDR and XDR TB strains (5,10). Our results support these observations; capreomycin resistance of MDR and XDR strains (17.5% and 94.4%, respectively) in Henan Province were higher than the average levels (10.2%, 62.5%, respectively) reported by a worldwide study (10). Pyrazinamide is an essential drug recommended by World Health Organization guidelines for treatment of MDR TB. Among the population with MDR TB that we studied, 10 (76.9%) of 13 XDR isolates were sensitive to pyrazinamide (data not shown), suggesting that pyrazinamide is still an effective first-line anti-TB drug for most XDR TB patients in Henan Province.
We restricted our investigation to 1 province. However, given the average national prevalence of XDR TB (8% of MDR TB) (1) and the magnitude of the population of Henan Province, our findings indicate that the prevalence of XDR TB might be higher in central China than previously documented.
Dawei Shi, Hui Li, Yuling Zhao, Qiong Jia, Christopher Coulter, Liang Li1, and Guofeng Zhu1Comments to Author 
Author affiliations: Institute of Pathogen Biology of Chinese Academy of Medical Sciences, Beijing, China (D. Shi, Q. Jia, G. Zhu); Peking Union Medical College, Beijing (D. Shi, Q. Jia, G. Zhu); National Institute for the Control of Pharmaceutical and Biological Products, Beijing (D. Shi); Henan Provincial Centers for Disease Control and Prevention, Zhengzhou, China (H. Li, Y. Zhao); Pathology Queensland, Brisbane, Queensland, Australia (C. Coulter); and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (L. Li)


This work was supported by China–Australia Health and HIV/AIDS Facility (FA10EID23), National Natural Science Foundation of China (30970117), and National Special Key Project of China on Major Infectious Diseases (2012ZX10003002-012).


  1. Zhao Y, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:216170. DOIExternal Web Site IconPubMedExternal Web Site Icon
  2. He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis. 2008;8:166. DOIExternal Web Site IconPubMedExternal Web Site Icon
  3. Deng Y, Wang Y, Wang J, Jing H, Yu C, Wang H, Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerg Infect Dis. 2011;17:4957. DOIExternal Web Site IconPubMedExternal Web Site Icon
  4. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:40757. DOIExternal Web Site IconPubMedExternal Web Site Icon
  5. Tang S, Zhang Q, Yu J, Liu Y, Sha W, Sun H, Extensively drug-resistant tuberculosis, China. Emerg Infect Dis. 2011;17:55860. DOIExternal Web Site IconPubMedExternal Web Site Icon
  6. Wang D, Yang C, Kuang T, Lei H, Meng X, Tong A, Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Jpn J Infect Dis. 2010;63:36871.PubMedExternal Web Site Icon
  7. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE. 2009;4:e4370. DOIExternal Web Site IconPubMedExternal Web Site Icon
  8. Shi D, Li L, Zhao Y, Jia Q, Li H, Coulter C, Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother. 2011;66:22407. DOIExternal Web Site IconPubMedExternal Web Site Icon
  9. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.WHO/HTM/TB/2008.392. Geneva: The Organization; 2008.
  10. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:3807. DOIExternal Web Site IconPubMedExternal Web Site Icon


Suggested citation for this article: Shi D, Li H, Zhao Y, Jia Q, Coulter C, Li L, et al. Extensively drug-resistant tuberculosis, central China, 2007–2009 [letter]. Emerg Infect Dis [Internet]. 2012 Nov [date cited]. http://dx.doi.org/10.3201/eid1811.120046External Web Site Icon
DOI: 10.3201/eid1811.120046
1These authors contributed equally to this article.

No hay comentarios:

Publicar un comentario